A new cost-effectiveness analysis suggests quality-adjusted life year gain and cost reduction for patients treated with axicabtagene ciloleucel versus tisagenlecleucel.
Rose McNulty
Advertisement
Rose is an editorial director at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Articles by Rose McNulty
The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.
An experimental safety switch incorporated into chimeric antigen receptor (CAR) T-cell therapy reduced the severity of the treatment’s side effects in an early-phase trial.
Updated lung cancer screening recommendations from the U.S. Preventive Services Task Force include 2 changes that will nearly double the number of people eligible for screening.
Research funded by the National Human Genome Research Institute has produced a 22-item guideline for the minimal polygenic risk score-related information that researchers should include in their studies.
A review published in Cancer examines the efficacy and drawbacks of tools used to evaluate health-related quality of life in immuno-oncology clinical trials.
A new study found that performing single-cell RNA sequencing on T cells circulating in the blood provided significant insight on sister cells within tumor tissue in advanced melanoma.
The FDA has granted full approval to lorlatinib, expanding its indication to include frontline treatment for patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.
Quick policy changes and the necessity to alter care delivery amid a global health crisis helped larger facilities adapt to the new realities of COVID-19.
A presentation at the ACCC 47th Annual Meeting & Cancer Center Business Summit gave virtual attendees an overview of research on PROs and how RSM can be incorporated into an oncology practice.
Kavita Patel, MD, MS, FACP, a fellow at the Brookings Institution Center for Health Policy, touched on key topics in health care at the ACCC 47th Annual Meeting and Cancer Center Business Summit.
Updates on Waldenström macroglobulinemia treatment formed by an international consensus panel were recently finalized and published in The Lancet Haematology.
Break Through Cancer, a collaborative research effort between 5 top US academic cancer centers, aims to pursue solutions to some of the most difficult challenges in cancer research.
Loading chimeric antigen receptor (CAR) T-cells with the oncolytic virus pelareorep improved their efficacy in solid tumor mouse models in a preclinical study presented at the CAR-TCR Summit Europe 2021.
Pivotal cancer clinical trial data may lack generalizability in older adults with Medicare, a study published online today in JAMA Network Open found.
The PD-1 inhibitor cemiplimab-rwlc, sold as Libtayo, was FDA approved as a monotherapy for patients with first-line advanced non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.
Patent foramen ovale (PFO) may be associated with migraine, especially migraine with aura (MA), when the PFO is permanent right-left shunt (RLS), large RLS, and large-size PFO, a recent study found.
Rates of central retinal artery occlusion (CRAO), which is associated with and shares common risk factors with cardiovascular diseases, have decreased over time in Korea, a recent cohort study of 50 million residents found.
ACCC president Randall Oyer, MD, gives insight into the ongoing collaboration between the ACCC and ASCO to foster minority participation in cancer clinical trials.
The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.
A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.
Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.
Sustained minimal residual disease (MRD) negativity may predict long-term outcomes in relapsed/refractory multiple myeloma (RRMM), and daratumumab-based combinations show higher rates of sustained MRD negativity compared with the standard of care.
Deferred low-dose computed tomography lung cancer screening during the coronavirus disease 2019 (COVID-19) pandemic has worsened outcomes for patients with lung cancer, a new study found.
The newly approved expanded label includes data from the final analysis of the phase 3 iNNOVATE study of ibrutinib plus rituximab vs rituximab alone.
Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.
Carfilzomib-dexamethasone improved renal overall and complete response in patients with relapsed or refractory multiple myeloma (RRMM) compared with a regimen of bortezomib-dexamethasone in a real-world study.
Advertisement
